Pfizer (PFE) Could Be 60% Below Fair Value On Tukysa Approval And Vaccine Data
Pfizer (PFE) Could Be 60% Below Fair Value On Tukysa Approval And Vaccine Data Simply Wall Street
Covered in this story
Analyst targets on Pfizer
- Cantor Fitzgerald: $28.3 → $28 by Oct 2027 · Neutral via TIKR.com
- Bank of America: $28.3 → $29 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: $28.3 → $30 by Oct 2027 · Neutral via The Globe and Mail
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 49 stories mentioning Pfizer, the earliest published 18 Jun 2026.
Summary aggregated from Simply Wall Street's public RSS feed. The full reporting belongs to Simply Wall Street — please read it on their site.